Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Cemiplimab in Resectable NSCLC, HCC, and HNSCC
NCT03916627Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2019
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of cemiplimab in non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC) and head and neck squamous cell carcinoma (HNSCC) (7 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Major pathologic response, Significant tumor necrosis and 1 more. Started Jul 2019; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03916627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916627.